Comparison of propofol with midazolam in endoscopic submucosal dissection for esophageal squamous cell carcinoma: a randomized controlled trial
- 439 Downloads
Interruption of sedation due to a poor response to modified neuroleptanalgesia (m-NLA) with midazolam often occurs during endoscopic submucosal dissection (ESD) for esophageal squamous cell carcinoma (ESCC) because most patients have a history of heavy alcohol intake. Recently, propofol has been used feasibly and safely during endoscopic procedures. The aim of this study was to clarify the efficacy and safety of propofol compared with that of midazolam during ESD for ESCC.
This was a single-blind, randomized controlled trial in a single center. Patients with ESCC scheduled for ESD were included in the study. Patients were randomly assigned to one of two groups: the propofol group and the midazolam group. The main outcome was the incidence of discontinuation of the procedure due to a poor response to sedation. Secondary outcomes included risk factors for a poor response to sedation.
Between April 2014 and October 2015, 132 patients (n = 66 per group) who underwent ESD for ESCC were enrolled in this study. The incidence of discontinuation due to a poor response to sedation in the propofol and midazolam groups was 0% (0/66) and 37.9% (25/66), respectively (p < 0.01). Multivariate analyses revealed that use of midazolam [Odds ratio (OR), 7.61; 95% confidence interval (CI), 2.64–21.92; p < 0.01] and age (OR, 0.93; 95% CI, 0.86–0.98; p < 0.01) were risk factors for a poor response to sedation.
Our study indicates that, compared with midazolam, propofol is a more efficient sedative for m-NLA during ESD for ESCC.
KeywordsSedation Propofol Midazolam Alcohol Endoscopic submucosal dissection Esophageal cancer
Compliance with ethical standards
Conflict of interest
Toshio Watanabe received a consulting fee from Eisai Co. Ltd.; Yasuhiro Fujiwara received a consulting fee from Ono Pharmaceutical Co. Ltd.; Tetsuo Arawaka received consulting fees from Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd, Astra-Zeneca Co. Ltd. and Tsumura Co. Ltd.